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Abstract
Glucocorticoids play important roles in the regulation of distinct aspects of adipocyte biology. Excess glucocorticoids in
adipocytes are associated with metabolic disorders, including central obesity, insulin resistance and dyslipidemia. To
understand the mechanisms underlying the glucocorticoid action in adipocytes, we used chromatin immunoprecipitation
sequencing to isolate genome-wide glucocorticoid receptor (GR) binding regions (GBRs) in 3T3-L1 adipocytes. Furthermore,
gene expression analyses were used to identify genes that were regulated by glucocorticoids. Overall, 274 glucocorticoid-
regulated genes contain or locate nearby GBR. We found that many GBRs were located in or nearby genes involved in
triglyceride (TG) synthesis (Scd-1, 2, 3, GPAT3, GPAT4, Agpat2, Lpin1), lipolysis (Lipe, Mgll), lipid transport (Cd36, Lrp-1, Vldlr,
Slc27a2) and storage (S3-12). Gene expression analysis showed that except for Scd-3, the other 13 genes were induced in
mouse inguinal fat upon 4-day glucocorticoid treatment. Reporter gene assays showed that except Agpat2, the other 12
glucocorticoid-regulated genes contain at least one GBR that can mediate hormone response. In agreement with the fact
that glucocorticoids activated genes in both TG biosynthetic and lipolytic pathways, we confirmed that 4-day glucocorticoid
treatment increased TG synthesis and lipolysis concomitantly in inguinal fat. Notably, we found that 9 of these 12 genes
were induced in transgenic mice that have constant elevated plasma glucocorticoid levels. These results suggested that a
similar mechanism was used to regulate TG homeostasis during chronic glucocorticoid treatment. In summary, our studies
have identified molecular components in a glucocorticoid-controlled gene network involved in the regulation of TG
homeostasis in adipocytes. Understanding the regulation of this gene network should provide important insight for future
therapeutic developments for metabolic diseases.
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Introduction
Glucocorticoids regulate many facets of energy metabolism.
Excessive glucocorticoid exposure, whether exogenous or endog-
enous, is associated with the development of metabolic syndrome,
a constellation of metabolic risk factors that include insulin
resistance, central obesity, dyslipidemia and hypertension [1,2].
Animal model studies, either applying genetic [3,4] or pharma-
cological approaches [5,6,7], have shown that reducing the
glucocorticoid signaling in vivo protects the animals from various
metabolic disorders and improves their metabolic profiles.
Intriguingly, several studies have shown that increasing active
glucocorticoid levels specifically in adipocytes can cause metabolic
syndrome [8,9]. Conversely, transgenic mice that have decreased
levels of active glucocorticoids in adipocytes are protected from
diet-induced obesity and have improved glucose tolerance and
insulin sensitivity [10]. Thus, these data highlight the critical role
of adipocytes in glucocorticoid-regulated energy homeostasis and
demonstrate that modulating glucocorticoid signaling in this cell
type exclusively can have significant impacts on whole body
metabolism.
In adipocytes, glucocorticoids modulate both glucose and lipid
homeostasis. For the former, glucocorticoids inhibit insulin-
stimulated glucose uptake [11,12,13]. For the latter, depending
on nutritional state, glucocorticoids exert distinct effects on lipid
metabolism, increasing lipogenesis in the fed state [14,15] and
increasing lipolysis in the fasted state [16,17,18]. Furthermore,
glucocorticoids promote re-distribution of body fat [19]. Patients
of Cushing’s syndrome, which is characterized by high plasma
cortisol levels, have fat accumulation in the depots of the
abdomen, the nape of the neck and the cheeks, but reduced fat
storage in other subcutaneous depots [20]. Overall, the effects of
glucocorticoids on lipid metabolism could be affected by other
environmental cue and are also region specific. It is important to
note that while the glucocorticoid-regulated metabolic phenotypes
are well described, the mechanisms underlying these metabolic
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15188effects are not entirely elucidated. Glucocorticoids exert their
biological functions through an intracellular glucocorticoid
receptor (GR). GR is a transcriptional regulator, which upon
binding to cognate ligands, occupies specific genomic GREs, and
modulates the transcription of nearby genes [21]. The products of
these ‘‘primary’’ target genes either directly affect cellular
physiology or modulate the expression of other sets of genes
(‘‘secondary’’ target genes), which then confer hormonal responses
[22]. Identifying primary target genes that initiate physiological
responses will shed new light on the mechanisms governing
glucocorticoid actions. In different cell types glucocorticoids affect
distinct physiological processes by inducing specific gene expres-
sion program. Notably, very few GR primary target genes in
adipocytes have been identified to date.
To identify GR primary target genes in adipocytes, in this
report, we applied a combination of chromatin immunoprecipi-
tation (ChIP) and a high throughput DNA sequencing technique
(called ChIPseq) to isolate genome-wide GR binding regions
(GBRs) in 3T3-L1 adipocytes. Intriguingly, we found that many
genes involved in TG homeostasis, including those in TG
biosynthetic and lipolytic pathways, contain or are located near
GBRs. We further investigated the regulation of these genes by
glucocorticoids in mouse adipose tissue. Moreover, to further
confirm that these genes are GR primary targets, GBRs from
distinct genes were inserted into a reporter plasmid to determine
whether they can mediate a glucocorticoid response. Finally, to
learn whether the glucocorticoid-induced gene expression change
translates to corresponding physiological outputs, we applied
stable isotope labeling technique to monitor the effect of
glucocorticoids on TG metabolism in vivo.
Methods
Cell culture
The 3T3-L1 (Mouse embryonic fibroblast-adipose like cell
line) cells, kindly provided by Dr. Hei Sook Sul (UC Berkeley),
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Mediatech) containing 10% fetal bovine serum (FBS;
Tissue Culture Biological) and incubated at 37uCw i t h5 %C O 2.
3T3-L1 cells at 2 days post-confluence were differentiated into
adipocytes using differentiation-inducing medium (1 mM dexa-
methasone (DEX), 0.5 mM methylisobutylxanthine, and
1.67 mM insulin in DMEM with 10% FBS). The 3T3-L1 cells
were maintained in differentiation media for 3 days. The cells
were then returned to medium consisting of 10% FBS in DMEM
without drugsfor an additional 3 days. Before embarking on a
ChIP-seq experiment, differentiated 3T3-L1 adipocytes were
washed with 16phosphate-buffered saline (16PBS buffer) and
cultured in DMEM supplemented with 5% stripped FBS (J.R.
Scientific) for 24 hours. 3T3-L1 adipocytes were then exposed to
500 nM dexamethasone (DEX) or an equal volume (0.05% v/v
of media) of ethanol as a vehicle control for 1 h at 37uCi n
DMEM with 5% stripped FBS.
Animals
Male 8-week-old C57BL/6 mice were purchased from Charles
River. Animals were injected daily with 5 mg/kg DEX (Sigma) or
PBS for 4 days. After 24 hours of the last injection, animals were
sacrificed for various assays. Transgenic mice overexpressing
corticotropin-releasing hormone (CRH) were provided by Mary
Stenzel-Poore [23]. The Office of Laboratory Animal Care at the
University of California, Berkeley (#R306-0111) approved all
animal experiments conducted in this paper.
ChIPseq
After 3T3-1L adipocytes were treated, DEX- or ethanol-
treated cells (two 15 cm plates for each treatment) were cross-
linked in 1% formaldehyde for 10 min at room temperature,
followed by quenching of the cross-linking reaction in 0.125 M
glycine for 5 min. After washing the cells with 16PBS, they were
lysed and scraped in cell lysis buffer (50 mM HEPES-KOH at
pH 7.4, 1 mM EDTA, 150 mM NaCl, 10% glycerol, 0.5%
Triton X-100) added with protease inhibitor cocktails (Calbio-
chem). The cell lysate was incubated for 10 min at 4uC and the
crude nuclear extract was collected by centrifugation at 6006g
for 5 min at 4uC. We resuspended nuclei in 1 mL of ice-cold
RIPA buffer (10 mM Tris-HCL at pH 8.0, 1 mM EDTA,
150 mM NaCl, 5% glycerol, 1% Triton X-100, 0.1% sodium
deoxycholate, 0.1% SDS, supplemented with protease inhibitor)
and fragmented chromatin to 200–500 bp with eleven pulses of
20 sec at 30% power with a Branson Sonifier 250 sonicator at
4uC. To remove insoluble components, we centrifuged the
samples at 13,000 rpm for 15 min at 4uC and recovered the
supernatant. The supernatant was then added to 1 mgo fr a b b i t
polyclonal anti-GR (N499) antibody to immunoprecipitate GR-
bound chromatin at 4uC overnight. We next added 100u of 50%
protein A/G plus-agarose bead slurry (Santa Cruz Biotechnology)
into each immunoprecipitation and incubated it for 2 h at 4uC.
After incubation, we washed the beads five times with RIPA
buffer containing 510 mM NaCl, followed by five times with LiCl
buffer (20 mM Tris at pH 8.0, 1 mM EDTA, 250 mM LiCl,
0.5% NP-40, 0.5% sodiumdeoxycholate, supplemented with
protease inhibitor) and five times with RIPA buffer containing
510 mM NaCl. After removing the remaining wash buffer, each
IP reaction was added to 75 mlo fp r o t e i n a s eKs o l u t i o n( T E
pH 8.0, 0.7% SDS, 200 mg/ml proteinase K) and incubated for
3 h at 55uC, followed by incubating overnight at 65uCt or e v e r s e
formaldehyde cross-links. We further purified the DNA with a
QIAquick PCR purification kit (Qiagen), eluting in 30 mlo f
Qiagen Elution Buffer.
For each ChIPseq experiment, we followed the procedures of
Illumina genomic DNA library preparation for sequencing. In
brief, ChIP DNA fragments were blunted and ligated to
sequencing adapters. The adapter-ligated DNA was amplified
with 25 rounds of PCR. We electrophoresed the amplified
products on a 2% agarose gel. We excised a region of gel
containing DNA fragments 150–300 bp in length and extracted
DNA from the gel slice with a Qiagen Gel Extraction kit. We then
ensured the DNA quality by Bioanalyzer (Agilent). The resulting
DNA library was sequenced on the Illumina Genome Analyzer
(Vincent J. Coates Genomic Sequencing Laboratory, UC
Berkeley). The reads that have passed Illumina’s internal quality
filter were retained for further analysis. Reads were aligned to
mm9 assembly of mouse genome by Illumina’s default aligner
ELAND (allowing up to 2 mismatches in first 32 bps). The aligned
reads were given as input to peak-finding software Model-based
Analysis of ChIPseq (MACS). The default p-value cutoff criterion
was at 10
25 (the effective genome size was set to 2.2 Gb). The
underlying DNA sequences of the identified peak regions were
obtained with a python script and further analyzed with web-
based motif-finding tools.
Annotation of genes
The distribution of GR-binding sites, relative to nearest genes,
was determined with PinkThing (http://pinkthing.cmbi.ru.nl). All
sequences associated with the peaks were obtained from the Mus
musculus NCBI m37 genome assembly (mm9; July 2007).
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BioProspector [24] was used to search for 14- or 8-bp motifs in
the ChIPseq data. The top 10–20 scoring output motifs from
BioProspector were then compared to known binding sites in
TRANSFAC V11.3 database using STAMP [25]. A motif
discovery program, cis-regulatory element annotation system
(CEAS) (http://ceas.cbi.pku.edu.cn) (Ji et al. 2006), was also
performed to obtain the enriched transcription factor motifs
located in ChIPseq-identified GBRs.
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/home.jsp) was
used to perform gene ontology analysis. Below are the list of
categories selected for analysis: Disease: OMIM_DISEASE, Func-
tional Categories: COG_ONTOLOGY, SP_PIR_KEYWORDS,
UP_SEQ_FEATURE, Gene_Ontology: GOTERM_BP_ALL,
GOTERM_CC_ALL, GOTERM_MF_ALL, PANTHER_BP_
ALL, PANTHER_MF_ALL, Pathway: BBID, BIOCARTA,
KEGG_PATHWAY.
RNA isolation and quantitative PCR
Total RNA was isolated from mouse inguinal fat using TRI
ReagentH RT (Molecular Research Center, Inc.). To synthesize
random-primed cDNA, 0.5 mg of total RNA, 4 ml of 2.5 mM
dNTP, and 2 ml of random primers (New England Biolabs) were
mixed at a volume of 16 ml and incubated at 70uC for 10 min.
Then, a 4-ml cocktail containing 25 units of Moloney Murine
Leukemia Virus (M-MuLV) Reverse Transcriptase (New England
Biolabs), 10 units of RNasin (Promega), and 2 mlo f1 0 6reaction
buffer (New England Biolabs) was added and incubated at 42uC
for 1 h. The reaction was then incubated at 95uC for 5 min. The
resultant cDNA was diluted to 200 ml, and 3.5 ml was used to
perform qPCR using EVA QPCR SuperMix Kit (Biochain) per
manufacturer’s protocol. qPCR was performed in either a
7900HT, 7500HT or StepOne PCR System (Applied Biosystems)
and analyzed by using the DD-Ct method as supplied by the
manufacturer (Applied Biosystems). Rpl19 gene expression was
used for internal normalization. Primer sequences are listed in
Table S2.
Plasmids, transfection, and luciferase reporter assay
pGL4.10-E4TATA reporter plasmid was generated by insertion
of a 50-bp minimal E4 TATA promoter sequence (Lin et al. 1988)
into the Bgl II to Hind III sites of vector pGL4.10 to drive luciferase
expression (Bolton et al. 2007). Each chosen GBR fragment,
extending 100–150 bp upstream and downstream, was amplified
from genomic 3T3-L1 DNA (primer sequences are listed in Table
S2) using Phusion High–Fidelity DNA Polymerase (New England
BioLabs) and cloned into the pGL4.10-E4TATA vector by either
Xho I/EcoR Vo rKpn I/Xho I sites. SuperFect transfection reagent
(Qiagen) was used to transfect 3T3-L1 preadipocytes in 12-well
plates according to the technical manual. Twenty-four hours post-
transfection, cells were treated with either 1 mM DEX or ethanol,
in DMEM with 5% stripped FBS for 24 hours. Cells were then
harvested, and luciferase activity was measured with a Dual-
Luciferase Reporter Assay kit (Promega), following the technical
manual.
Measurement of triglyceride concentration and synthesis
by stable isotope
Mice were administered by an intraperitoneal injection of heavy
water (
2H2O)(0.035 ml/g body weight of 100% atomic percentage
excess
2H2O), and they were maintained on 8%
2H-labeled
drinking water for 7 days. After 3 days of giving 8%
2H-labeled
drinking water, mice were treated with DEX (5 mg/kg body
weight) or PBS for 4 consecutive days. The mice were sacrificed,
and inguinal fats were collected to measure the rate of TG
synthesis as previously described (Bederman et al. 2009). The TG
composition of inguinal fats was studied using a thin layer
chromatography (TLC) method, which begins with briefly
homogenizing inguinal fat samples in Tris Sucrose buffer
(50 mM Tris-HCl at pH 7.4, 250 mM sucrose, supplemented
with protease inhibitors). Lipids were extracted using chloroform:-
methanol (2:1) and separated on Whatman* Adsorption 60A ˚ Silica
Gel TLC Plates with the solvent hexane:ethyl ether:acetic acid
(v:v:v80:20:1). TLC plates were exposed to iodine vapor in order
to visualize the TG bands. The TG bands were scraped and added
to 1 ml of a 1:1 mixture of the 8% ethanolic NaOH and 4%
hydroxylamine solution. The TG reaction was thoroughly
vortexed and incubated at 65uC for 2 minutes. The TG samples
were cooled for 5 minutes at room temperature and 2.5 ml of fresh
ferric perchlorate reagent was added. Next, 250 ml of each TG
sample was loaded in a 96 well ELISA plate with a serial dilution
of 250 mM Triolein (Sigma) as a set of standards. The plate was
read at 530 nm after 30 minutes. The TG levels were calculated
and expressed as mmol per mg tissue weight. To make the fresh
ferric perchlorate reagent, 5 g of ferric perchlorate was dissolved
in 10 ml of 70% HClO4 and 10 ml of water. This solution was
diluted with 80 ml cold 100% ethanol to make a stock ferric
perchlorate solution. 4 ml of the stock ferric perchlorate solution
was then combined with 3 ml of 70% HClO4 and 93 ml cold 95%
ethanol.
Lipolysis Assay
The lipolysis assay was conducted as previously described
(Jaworski et al. 2009). Explants from freshly removed inguinal fat
pads (,100mg) were incubated at 37uC in 500uL Krebs-Ringer
Buffer (12mM HEPES,121mM NaCl, 4.9mM KCl, 1.2 mM
MgSO4 and 0.33mM CaCl) with 3% BSA and 3mM glucose.
Glycerol release was determined over time using free glycerol
reagent (Sigma). Measurements were normalized to total protein
content of the adipose sample using Bradford protein dye
(BioRad).
Microarrays and Data Analysis
3T3-L1 adipocytes were cultured in DMEM supplemented with
5% stripped FBS (J.R. Research) for 24 hours and then treated
with 500 nM DEX or an equal volume (0.05% v/v of media) of
ethanol as a vehicle control for 6 hours at 37uC in DMEM with
5% stripped FBS. Total cellular RNA was isolated utilizing the
NucleoSpin RNA II kit (Macherey-Nagel). RNA isolates were first
quantified by standard spectrophotometry, and then qualitatively
evaluated by capillary electrophoresis employing the Bio-Rad
Experion system per the manufacturer’s instruction. Biotin-labeled
cRNA samples were prepared with 750 ng of total RNA template.
Following synthesis and purification, the biotin-labeled samples
were evaluated by both 260/280 absorbance spectrophotometry
and capillary electrophoresis. The final labeled cRNA samples
were hybridized overnight against 48,000 transcripts using
MouseWG-6 BeadChip arrays (Illumina, San Diego, CA). The
Illumina microarrays were processed at the UCSF Genomics
Core. All treatments were done in triplicates, and the same batch
of microarrays was used for all treatments. The Illumina
expression arrays were pre-processed using lumi package [26].
The differential expression analysis was performed using the
Limma package [27]. These packages are all available in R/
BioConductor. Probes were selected for further analysis if the fold-
induction was greater than 2 and multiple testing adjusted the p-
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(BH-adjusted p-value) [28]. The heatmaps of log intensities of
genes across different experiments were produced using Cluster
and TreeView software [29]. The microarray data is available at
the Gene Expression Omnibus Web site (http://www.ncbi.nlm.
nih.gov/geo/) under accession No. GSE24105.
Results
Identification of genome-wide GR binding regions in
3T3-L1 adipocytes
We used ChIPseq to identify the genomic locations bound by
mouse GR in 3T3-L1 adipocytes in response to the treatment of a
synthetic glucocorticoid, dexamethasone (DEX). We sequenced
the ChIP DNA with an Illumina Genome Analyzer and aligned
the sequence reads to the mouse genome using Illumina’s ELAND
program. Model-based Analysis of ChIPseq (MACS) algorithm
was then used to identify enriched genomic regions in DEX-
treated samples vs. ethanol-treated samples. When p value,10
25
was used, we identified 8,848 genomic positions occupied by GR
upon DEX treatment. We used PinkThing (http://pinkthing.
cmbi.ru.nl) to assign GBRs to mouse genes based on proximity,
and target sites were grouped depending on their position relative
to the nearest gene. Fig. 1A is an example of these analyses. In
chromosome 19, downstream of the Scd-2 gene, we identified two
GBRs, as the number of sequencing reads at these two regions
were significantly enriched in DEX-treated samples than in
ethanol-treated samples (Fig. 1A). A complete list of binding sites
at all significant thresholds is available in Dataset S1. Overall, GR
preferentially bound in the intron regions (48%, Fig. 1B). 13% of
GBRs were located between 5–50 kb 59 of transcription start site
(TSS), whereas 17% were located within 50 kb from 39 of stop
codon (Fig. 1B). Interestingly, only 6% of GBRs were located
inside of 5 kb from TSS (Fig. 1B). Furthermore, 16% of GBRs
were located 50 kb upstream of TSS or 50 kb downstream of the
stop codon (Fig. 1B). Other studies using ChIPseq or ChIP on chip
to isolate binding sites for nuclear receptors also showed that only
approximately 10% of binding sites are located inside of 5 kb from
the TSS, whereas the majority of binding sites were located in the
intron and/or far distant region [30,31,32,33,34,35].
Identifying GR-regulated Genes in 3T3-L1 Adipocytes
using microarray
Potential GR primary target genes that contain or are located
nearby GBRs should have expression regulated by glucocorticoids.
Figure 1. Genomic distribution of glucocorticoid receptor binding sites binding sites and response elements. A) An example of
ChIPseq data showing the number of ChIPseq sequencing tag in Scd-2 gene. ChIP-seq data are plotted as the density of 36-bp tags mapping to the
region. The density is separated to show the reads (Y-axis) mapping to the reference genome (X-axis) in DEX (red) or ethanol (black) treated samples.
B) Enrichment of GBRs in genomic features. The percentage of all identified GBRs in each type of region was shown.
doi:10.1371/journal.pone.0015188.g001
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performed microarray analyses to isolate genes whose expression is
modulated by glucocorticoids upon 6-hour-DEX treatment in
3T3-L1 adipocytes. We found that 421 genes were significantly
induced by DEX by more than 1.5 fold. Among these genes, 292
genes contain GBRs in their genomic regions, or GBRs located
within 100 kb upstream of their TSS or within 100 kb
downstream of their stop codon (Table 1). In contrast, 198 genes
were inhibited by DEX by more than 1.5 fold. Among these genes,
45 genes contain GBRs in their genomic regions, or GBRs are
located within 100 kb upstream of their TSS or within 100 kb
downstream of their stop codon (Table 1). All of the 620 DEX-
regulated genes identified by microarray are shown in Dataset S2.
Overall, we identified 337 glucocorticoid responsive genes (Dataset
S3), which had their expressions modulated, up or down, by
glucocorticoids in 3T3-L1 adipocytes, and they contain or are
located nearby GBRs.
We used a web-based gene ontology tool, DAVID, to classify
these 337 glucocorticoid responsive genes. The top categories of
genes identified in the functional annotation chart include those
involved in the regulation of distinct developmental processes, such
as blood vessel and mammary gland formation, and the regulation
of apoptosis, cell proliferation and signal transduction (Dataset S4).
Moreover, genes involved in lipid metabolism are also significantly
presented (Dataset S4). The genes identified in each category of
gene ontology are shown in Dataset S4. Notably, among these 337
genes, Dusp1 [36], Insig2 [37], Lcn2 [38], Pik3r1 [39], and Ptgds [40]
have been previously shown to regulate the insulin action in
adipocytes. The overexpression of Dusp1, Insig2,a n dLcn2 has been
linked to the development of insulin resistance. Thus, the induction
of these three genes by glucocorticoids is consistent with their
repressive effect on insulin-stimulated glucose uptake. Conversely,
Ptgds play a positive role in the regulation of insulin-stimulated
glucose uptake. Moreover, several potential GR primary targets are
previously shown to be involved in the adipogenesis: Ctsl[41], Dusp1
[42], Insig2 [43], Lpin1 [44], Ptgds [45], Rgs2 [46], Scd2 [47], Sgk1
[48]. Tsc22d3, however, was found to inhibit the adipocyte
differentiation [49]. Finally, some potential target genes are the
components of the signaling pathways regulating adipogenesis, such
as TGFß (Smad3, FST, and Lox) [50] and wnt (FZD1) [51].
We performed a combination of Bioprospector [24] and
STAMP [25] to search for consensus motifs within GBRs located
in or nearby genes that were induced or repressed by
glucocorticoids. In Bioprospector, either a width of 14 or 8 was
used for the analyses. For glucocorticoid-activated genes, a motif
for GRE was highly represented from these analyses (Fig. 2A). The
motif for GRE is usually similar to that of ARE (androgen
response element). Interestingly, these the analysis suggested that
heat shock factor (HSF) could also bind to this similar motif.
Furthermore, the rest of the binding motifs other than GRE
include FOXP1, STE11, HFH4, FOX, FOXD3, UF1H3beta,
BR-C, ZNF219, E4BP4, C/EBP, HNF3alpha (aka FOXA1),
CAC-binding, AtMYB-84, GBF, PAX-4, MAZR, KROX,
NKX6.1 and PXR (Fig. 2B). For glucocorticoid-repressed genes,
binding motifs for GR and AR were still highly representative
(Fig. 2C). In addition, HSF, STE11, PPAR, NaNog, MAZ, PAX,
BR-C binding sites were significantly present (Fig. 2D). Compar-
ing motifs identified between glucocorticoid-activated and re-
pressed genes, four motifs GR BR-C, PAX and STE11 are present
in both groups of genes. However, there are also motifs that
are specifically represented in either glucocorticoid-activated or
-repressed genes.
Characterization of Glucocorticoid-regulated Genes
Involved in TG Homeostasis
Gene ontology analysis showed that glucocorticoids regulate
genes involved in distinct aspects of lipid metabolism (Dataset S4).
In this list, several genes regulate TG homeostasis—Scd-2, Vldlr,
GPAT3 and Lpin-1 (Dataset S4). Cd36 has also been shown to play
a role in fatty acid transport. Furthermore, ChIPseq identified
several other genes involved in TG homeostasis, even though they
were not regulated by 6-hour-DEX treatment in 3T3-L1
adipocytes. These genes include those involved in TG synthesis
(Scd-1, Scd-3, GPAT4, Agpat2), lipolysis (Lipe and Mgll), lipid
transport (Lrp-1, Slc27a2), and lipid storage (S3-12). It is possible
that some of these genes are regulated at DEX-treatment-time
points other than 6-hours. Alternatively, some of these genes may
only be regulated in vivo, a condition that cannot be recapitulated
by in vitro cell culture model, even though the GR binding
phenotype is conserved in 3T3-L1 adipocytes. Overall, there are
14 genes involved in TG homeostasis in the gene list from
ChIPseq, and we decided to further the studies in vivo, to
determine whether these genes are regulated by glucocorticoids.
The rationale in vivo studies is to allow us to monitor the in vivo
metabolic effects of glucocorticoids in conjunction with gene
expression analysis. Mice were treated with either 5 mg/kg DEX
or equal volume of PBS for 4 days. The expressions of all 14 genes
were significantly induced by DEX treatment in inguinal fat
except for Scd-3 (Table 2). In contrast, the effects of DEX on these
genes in epididymal fat depot were minimal (data not shown).
The keycriterionfor a primary target gene is that its transcription
is directly regulated by GR. Thus, its GBR(s) should contain
functional GRE(s) that can mediate glucocorticoid response. To test
whether GBRs from genes involved in TG homeostasis can confer
hormonal response, each GBR was inserted in front of a TATA box
of a heterologous reporter plasmid that drives a firefly luciferase
gene (pGL4.10-TATA). Most of these genes contain or locate
nearby multiple GBRs (Dataset S1). We subcloned each individual
GB into the PGL4.10-TATA. The entire collection of reporter
plasmids used in this report is listed in Table S1. These reporter
plasmids were transfected into 3T3-L1 preadipocytes. 16–24 hours
after transfection, cells were treated with either DEX or ethanol.
Table 1. Number of Genes Regulated by Glucocorticoids and containing GBRs in 3T3-L1 Adipocytes.
Glucocorticoid-regulated genes
Glucocorticoid-regulated genes
containing GBRs*
% of Glucocorticoid regulated genes
containing GBRs*
Activated 421 292 59%
Repressed 198 45 23%
Total 619 337 54%
*GBRs are located in the intron or within 100kb upstream from the TSS or 100kb downstream from the stop codon.
doi:10.1371/journal.pone.0015188.t001
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lysed and luciferase activities were measured. We found that except
for Agpat2, all other genes had at least one GBR that conferred
hormonal response (Fig. 3). Overall, these results suggested that 12
of these 13 displayed genes were potential GR primary target genes.
Glucocorticoids activated both TG synthesis and lipolysis
in mouse inguinal fat pad
Our data showed that in the inguinal fat depot, 4-day DEX
treatment concomitantly induced the expression of primary target
genes encoding enzymes in TG biosynthesis and lipolysis, two
Figure 2. GREs and other cis-regulatory motifs are enriched within GBRs. Unbiased motif search for GBRs in or nearby glucocorticoid-
activated and –repressed genes. A) Bioprospector analysis identified a motif that is highly similar to a consensus GRE in STAMP for glucocorticoid-
induced genes. B) Bioprospector and STAMP identified putative motifs for other transcription factors in GBRs of glucocorticoid-activated genes. Top
15 motifs other than GRE were shown. C) Bioprospector analysis identified a motif that matches a consensus ARE in STAMP in glucocorticoid-
repressed genes. Notably, the sequences of this consensus ARE is very similar to those of consensus GRE. D) Bioprospector and STAMP identified
putative motifs for other transcription factors in GBRs of glucocorticoid-repressed genes. Top 15 motifs other than ARE/GRE were shown.
doi:10.1371/journal.pone.0015188.g002
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DEX treatment affected both pathways in vivo. Stable isotope
(heavy water) labeling technique was employed to label any newly
synthesized TG-glycerol in the mice. The rate of TG synthesis can
then be measured based on the percentage of deuterium
incorporated into the TG-glycerol molecule. We found that TG
synthesis rate in inguinal fat pad of DEX-treated animals was
significantly higher than that of PBS-treated animals (Fig. 4A).
If glucocorticoids only increased the rate of TG synthesis, it
would result in an elevated accumulation of TG levels in the
inguinal fat pad. At the same time, if glucocorticoids also activated
lipolytic pathways, the newly synthesized TG would be degraded
instead of accumulated in adipose tissue. We proceeded to
measure the TG levels in inguinal fat pad after 4-day-DEX or
PBS treatment. Our results show that the TG levels were not
significantly different between DEX- or PBS-treated animals
(Fig. 4B). Furthermore, the weight of inguinal fat pad was not
significantly different between DEX- and PBS-treated animals
(Fig. 4C). Thus, these results indicated that 4-day-DEX treatment
also activated lipolysis in inguinal fat pad. T further confirm that
DEX induced lipolysis in inguinal fat, mice were treated with
DEX for 4 days. At the end of treatment, inguinal fat pads were
isolated and incubated in Krebs-Ringer Buffer. We then measured
the glycerol levels in the buffer after 1, 2 and 4 hours. We found
that the levels of glycerol released from DEX-treated inguinal fat
pads were significantly higher than those of PBS-treated inguinal
fat pads (Fig. 4D). Thus, these data demonstrated that DEX
treatment for 4 days enhances lipolysis in inguinal fat depots.
Overall, these in vivo results were in agreement with the fact that
4-day-DEX treatment induced genes encoding enzymes in both
TG biosynthetic and lipolytic pathways.
Increased expression of specific glucocorticoid-regulated
genes in inguinal fat of mice overexpressing
corticotropin-releasing hormone (CRH)
We next investigated whether the expression of these 12
glucocorticoid-regulated TG homeostasis-related genes was ele-
vated in inguinal fat of mice overexpressing CRH (CRH-Tg) [23]
CRH overexpression causes an increase of adrenocorticotropic
hormone (ACTH) secretion from pituitary, which in turn elevates
the secretion of corticosterone from adrenal gland. These mice,
thus, have chronic high levels of corticosterone, which resemble
human patients with Cushing’s syndrome. Interestingly, the
inguinal fat of these mice was found to have increased rates of
both TG synthesis and lipolysis concomitantly (DJ Roohk and C
Harris, personal communication). This phenotype is similar to
mice injected with DEX for 4 days in our studies. We found that
the expression of 9 of these 12 genes were significantly higher in
the inguinal fat of CRH-Tg than in wild type mice (Fig. 5). These
genes include those involved in both TG biosynthetic (GPAT3,
GPAT4 and Lpin1) and lipolytic (Lipe and Mgll) pathways. These
results suggested that most of the potential GR primary targets
identified in this study were involved in the regulation of TG
metabolism in the adipose tissue upon chronic glucocorticoid
treatment.
Discussion
In this report, we provide three major findings. First, we
present a list of GR primary target genes in adipocytes.
Glucocorticoids have been shown to modulate the expression of
certain genes in adipocytes previously, but it is unclear whether
these genes are directl regulated by GR. Examples include Scd-1
[52], Vldlr [53] and Lipe [54]. Here, we show that they are directly
regulated by GR. These results and other novel GR primary
genes identified from this study shine new light in the
mechanisms of GR-regulated biological pathways in adipocytes.
Second, we have identified genome-wide GBRs, which allows
further elucidation and comparison of the mechanisms of GR-
regulated transcription on distinct target genes in adipocytes.
Finally, we show that, in adipose tissue, glucocorticoids are
capable of increasing the rate of TG synthesis and lipolysis
concurrently. We also identify the potential GR primary target
genes involving in this process.
In our ChIPseq experiments in 3T3-L1 adipocytes, 8,848 GR
binding sites are identified from the mouse genome. A similar
range of number of binding sites were isolated using ChIPseq in
other laboratories. Reddy et. al. identified 4,392 GR binding sites
in human lung adenocarcinoma cells, A549 [33]. In human breast
cancer cells, MCF7, 10,205 estrogen receptor binding sites were
identified [32]. Furthermore, more than 5,000 peroxisome
proliferator activated receptor gamma binding sites were isolated
in murine 3T3-L1 cells [34] [55]. Steger et. al. recently identified
4,007 GR binding sites in 3T3-L1 preadipocytes [56]. Similar to
our findings, these reports also showed that ,10% of binding sites
are located within 5 kb from the TSS. Conversely, significant
numbers of binding sites are located in regions far distant from the
TSS or introns. It is important to note that many of these intronic
and long-range GR binding sites did mediate glucocorticoid
response when placed in front of a TATA box in a heterologous
reporter plasmid in our experiments. These results strongly suggest
that they are functional GREs. Notably, GBRs located far away
from the TSS are capable of interacting with basal transcription
machinery [57]. Nonetheless, the configurations of these synthetic
reporter constructs are not identical to their chromosomal context.
Ultimately, disruption of an enhancer in the context of whole
genome is needed to test its importance for the regulation of a
given gene in vivo. Therefore, to study the transcriptional
regulatory mechanisms of these binding sites in the natural
chromosomal context will be a critical challenge for understanding
GR action.
Table 2. The Regulation of Genes Involved in TG Homeostasis
by DEX.
Fold Induction SEM P Value
TG Synthesis Scd1 1.43 0.3 0.05
Scd2 2.46 0.48 0.007
Scd3 1.43 0.27 0.14
Gpat3 1.98 0.20 0.001
Gpat4 1.48 0.28 0.01
Agpat2 1.77 0.22 0.003
Lipin1 1.82 0.2 0.001
Lipolysis Lipe 1.9 0.24 0.001
Mgll 4.0 0.83 0.001
Lipid Transport Cd36 1.68 0.17 0.006
Lrp1 2.32 0.35 0.001
Vldlr 2.07 0.37 0.02
Slc27a2 3.17 1.27 0.01
Lipid Storage S3-12 4.15 0.7 0.006
The fold induction of gene expression by DEX treatment (DEX/PBS) was the
average of 10–12 mice used in each group.
doi:10.1371/journal.pone.0015188.t002
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significantly regulated by DEX in a microarray experiment.
Notably, the analysis of gene expression using microarray could
miss specific splicing variants of certain genes; it is likely that more
genes are regulated by glucocorticoids in this ChIPseq list. Some of
these genes have been previously shown to participate in the
regulation of insulin signaling and adipogenesis. However,
whether these sets of target genes can mediate the glucocorticoid
response will require further study. From our gene ontology
analysis, genes involved in angiogenesis and blood vessel
development are significantly represented. As angiogenesis plays
a role in the expansion of adipose tissues, it would be interesting to
investigate whether glucocorticoids affect this process in vivo in
future experiments. It is important to note that the biological
functions of many of these 337 genes in adipocytes have not been
studied. The identification of their biological functions provides
new insights for glucocorticoid biology in adipocytes.
Consensus motif analyses suggest that predicated GRE sequences
are located in or nearby most glucocorticoid-activated genes.
Interestingly, the predicated GRE motif is also highly represented in
GBRs of glucocorticoid-repressed genes. Whether these predicated
GRE motifs mediate the repressive effect of GR will be an
important topic in our future studies. GR frequently represses the
transcription through tethering GREs, at which GR does not bind
to DNA directly; instead it is recruited to GREs through interaction
withothertranscription factors.TwomostcommontetheringGREs
are NFkB and AP-1 response elements [58]. However, in our
bioinformatics analyses, these two binding motifs are not among the
most representative sequences in GBRs of glucocorticoid-repressed
genes. Instead, the motifs identified have not been linked to the
repressive effect of GR (Fig. 2D). C/EBP and HNF3alpha, two
families of transcription factors whose binding motifs are highly
represented in GBRs of glucocorticoid-activated genes, were
previously shown to act with GR to participate in glucocorticoid-
activate gene transcription [59,60,61,62]. The HNF3alpha binding
motif is similar to those of the FOX family transcription factors.
HNF3alpha and FOX are also represented in GBRs of glucocor-
ticoid-induced genes. Notably, the interaction between GR and
other transcription factor binding motifs identified in GBRs of
glucocorticoid-activated genes has not been reported. Overall, these
analyses identify potential novel interactions between GR and other
transcription factors in adipocytes. We shall further investigate the
biological relevance of these possible interactions in future
experiments.
Figure 3. Glucocorticoid responsiveness of GBRs. Reporter plasmids that harbor distinct GBRs were co-transfected with pcDNA3-hGR (150 ng)
and pRL (100 ng) into 3T3-L1 preadipocytes in a 24-well plate (n=6 per group). pRL plasmid provided Renilla luciferase expression to document
transfection efficiency. Transfected cells were left overnight, then washed with PBS and treated with 0.5 mM DEX for an additional 16–20 hrs. Cells
were then lysed and assayed for firefly and Renilla luciferase activities. Data shows fold-induction of luciferase activity (DEX/ethanol treated samples)
from at least 6 experiments (*, p,0.05). The error bars represent the S. E. for the fold induction. The dashed-line represents one fold.
doi:10.1371/journal.pone.0015188.g003
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metabolism (Dataset S4). In this report, we focus on their effects on
TG homeostasis. We are the first to show that Scd-1, 2, GPAT3,
GPAT4 (TG synthesis), Lipe, Mgll (lipolysis), Cd36, Vldlr, Lrp-1,
Slc27a2 (lipid transport), S3-12 (lipid storage) are likely directly
regulated by GR based on the fact that their expressions are
regulated by glucocorticoids and they have functional GBRs.
Although Scd-1 [52], Vldlr [53] and Lipe [54] have previously been
shown to be regulated by glucocorticoids in 3T3-L1 cells or
primary adipocytes, the location of their GREs were not reported
until now. Involved in TG synthesis, Lpin1 was previously shown
as a GR primary target. The GRE identified is located between
2311 and 2297 of Lpin1 promoter (relative to TSS, whose
chromosomal location is chr12: 16615250 based on mm8
assembly or chr12: 16597172 based on mm9 assembly) [63]. In
our ChIPseq experiment, we identified a GBR that is approxi-
mately 200–400 bp away from this GRE (Dataset S1, row 1474).
It is possible that this GBR is from the recruitment of GR to
previously identified GRE. In addition, we found two GBRs that
are located ,1 kb apart between 226,920 and 227,250 (LPIN1-
GBR1) and 227,980 and 229,022 (LPIN1-GBR2) of the Lpin1
gene. Both GBRs identified in our studies were highly responsive
to DEX in reporter assays, especially LPIN1-GBR2 (Fig. 3). Thus,
it is possible that Lpin1 is regulated by multiple GREs. Notably,
Figure 4. The glucocorticoid effect on TG metabolism. A). The effect of DEX on inguinal fat TG synthesis rate. The error bars represent the S. E.
for the rate of TG synthesis (g of TG/week), with * representing a p value,0.05. B) Inguinal fat TG content measured by TLC from the same mice as in
A). The error bars represent the S. E. for the TG concentration. C) Inguinal fat pad weight after the treatment of PBS or DEX for 4 days. The error bars
represent the S. E. for the weight of inguinal fat pad. The p value for this experiment is 0.09. D) The effect of DEX on inguinal fat pad lipolysi. The error
bars represent the S. E. for the glycerol release (mg) per mg tissue protein with the * representing a p value,0.05. 10–12 animals are used in all four
experiments.
doi:10.1371/journal.pone.0015188.g004
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vivo but not in 3T3-L1 adipocytes. In fact, Lipe was found induced
by glucocorticoids in rat primary adipocytes, but its expression was
not activated by glucocorticoids in our experiments. There are
several possible explanations for these observations. It is possible
that the regulation of these genes by glucocorticoids require
specific transcriptional factors or cofactors that are expressed at
low levels in 3T3-L1 cells. Another possibility is that the regulation
of these genes by glucocorticoids may require the assistance of
other signals, which are not active in 3T3-L1 adipocytes. We are
currently investigating the regulation of these genes in primary
adipocytes to further understand how glucocorticoids regulate
these genes.
Interestingly, two 1-acylglycerol-3-phosphate O-acyltransferases
(Agpats) contain GBRs in their genomic regions: Agpat3 [64] and
Agpat4 [65] (Dataset S1). We find that the expression of Agpat3 and
4 is not affected by 4-day DEX treatment in inguinal fat (data not
shown). However, Agpat4 expression is induced in 6-hour-DEX
treatment in 3T3-L1 adipocytes and 24-hour-DEX treatment in
mice, and Agpat3 expression is elevated in inguinal fat of CRH-Tg
mice (data not shown). Interestingly, the GBRs of Agpat4 are able
to mediate glucocorticoid response when inserted into a reporter
plasmid (data not shown). Thus, Agpat4 is a potential GR primary
target. Our ChIPseq also located a GBR in the Angptl4 gene
(Dataset S1), which is involved in adipose tissue lipolysis [66]. This
GBR is located downstream of the stop codon of mouse Angptl4
gene, in a similar location to the GRE we previously identified in
rat Angptl4 gene [67]. As we previously presented, Angptl4 gene is
not regulated by glucocorticoids in 3T3-L1 adipocytes, but its
expression is induced by DEX treatment in epididymal fat pad
[67]. Overall, the identification of these novel GBRs in these genes
involved in TG homeostasis should facilitate future studies on how
glucocorticoids regulate their transcription and TG metabolism.
Notably, genes involved in lipid metabolism were not enriched
in GBRs identified in 3T3-L1 preadipocytes. We compared GBRs
identified in our studies and 3T3-L1 preadipocytes [56], and
found that 1,804 binding sites are common (Dataset S4). In 337 of
the glucocorticoid responsive gene identified in 3T3-L1 adipo-
cytes, 153 genes have GBRs in this list of 1,804 overlapping
binding sites (Dataset S5). When we compared the list of 29 genes
involved in lipid metabolism in adipocytes with these 153 genes,
we found 11 genes were overlapped (Dataset S5). Among 12
glucocorticoid responsive genes involved in TG homeostasis, the
GBRs for Gpat3, S3-12, Mgll, Lipe, Lrp1, and Slc27a2 were not
found in 3T3-L1 preadipocytes ChIPseq. As the biological role of
glucocorticoids somewhat differs in preadipocytes and adipocytes
(differentiation vs. metabolism), it is not a surprise that GR
regulates distinct sets of genes in these two cell types. More
detailed analyses of transcriptional regulatory mechanism of each
of these genes will be required to learn the mechanism governing
this differential regulation. Interestingly, a recent study showed the
distinct genome-wide chromatin marks between preadipocytes and
adipocytes [68]. This may affect the recruitment of GR to certain
GBRs in genome.
Applying stable isotope labeling technique, we find that the rate
of TG synthesis in the inguinal fat pad of 4-day DEX-treated
animals is higher than that of PBS-treated animals. However, the
levels of TG in inguinal fat pad are not significantly different
between DEX- and PBS-treated animals. This indicates the
activation of lipolysis, which is in agreement with the fact that
Figure 5. Comparing the expression of glucocorticoid-regulated genes in inguinal fat of CRH-Tg and wild type mice. Total RNA of
inguinal fat of wild type and CRH-Tg mice were isolated and converted to cDNA. Real-time PCR was then performed to monitor the expression of
genes indicated. Data shows fold-induction of gene expression (CRH-Tg/wild type) from 6–8 mice (*, p,0.05). The error bar represents the S.E. of the
fold induction.
doi:10.1371/journal.pone.0015188.g005
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both TG synthesis and lipolysis. Although previous studies have
independently shown that glucocorticoids either stimulate lipolysis
or TG synthesis (19), our results are first to show that
glucocorticoids activate both pathways in the same fat depot.
Thus, glucocorticoids appear to cause futile cycling in inguinal fat,
in which TG was continuously synthesized and degraded in our
experimental condition. These newly generated fatty acids could
have three routes. First, fatty acids can be re-incorporated into TG
in adipocytes. Second, these fatty acids could re-distribute to liver
and skeletal muscle, where they were re-synthesized to TG. We
have previously observed the increased TG levels in liver upon 4-
day DEX treatment [67], and an increase level of TG in skeletal
muscle has been previously reported [69]. Finally, fatty acids could
also be oxidized. It is unclear why glucocorticoids induce this type
of futile cycling in the adipose tissue. It is possible that during the
stress condition, glucose needs to be preserved, and the role of
glucocorticoids in adipose tissue is to provide fatty acids to plasma,
so other tissues can use them as energy sources.
Importantly, the expression of most GR responsive genes
identified in this study is also increased in CRH-Tg mice with a
chronic elevation of plasma corticosterone levels. The lipid
phenotypes of these mice are somewhat similar to the mice
treated with DEX for 4 days in our study (Donald J. Rhook and
Charlie Harris, personal communication), as the rates of TG
synthesis and lipolysis are induced at the same time in the
inguinal fats of both types of mice. These results suggest that most
genes identified from this study also participate in the long-term
glucocorticoid effect on TG metabolism. In human, chronic
glucocorticoid treatment causes lipid re-distribution between
distinct fat depots, it is possible that longer treatment of
glucocorticoids leads to distinct local environments at different
fat depots, at which specific hormonal and/or autocrine/
paracrine factors act together with glucocorticoids to differentially
regulate the TG biosynthetic or lipolytic primary target genes
identified in this report. Future studies should investigate this
model.
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Dataset S1 GBRs identified from ChIPseq. GBRs were
identified using MACS as described in Methods. The distribution
of GR-binding sites, relative to nearest genes, was determined with
PinkThing (http://pinkthing.cmbi.ru.nl). All sequences associated
with the peaks were obtained from the Mus musculus NCBI m37
genome assembly (mm9; July 2007).
(XLS)
Dataset S2 Genes regulated by DEX in 3T3-L1 adipo-
cytes. Microarray was performed as described in Methods. Genes
that are induced or repressed by DEX treatment for more than 1.5
fold with p value,0.05 are listed.
(XLS)
Dataset S3 GR-regulated Genes containing or locating
nearby GBRs in 3T3-L1 adipocytes. The overlapping genes
identified in both ChIPseq (Dataset S1) and microarray (Dataset
S2) were isolated by a web-based bioinformatic tool, Venn
Diagram Generator (http://www.pangloss.com/seidel/Protocols/
venn.cgi). DEX-activated or repressed genes are shown separately.
(XLS)
Dataset S4 Gene Ontology Analysis of Glucocorticoid
Responsive Genes. Glucocorticoid responsive genes analyzed
using gene ontology software (described in Methods). The genes
identified in top categories of the functional annotation chart are
shown.
(XLS)
Dataset S5 Overlapping GBRs identified in 3T3L1
adipocytes and preadipocytes. The overlapping 1,804 GR
binding regions in 3T3-L1 preadipocytes (56) and adipocytes (this
report) were shown. Furthermore, genes that locate nearest to
these 1,804 GR-binding regions are shown.
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Table S1 Reporter Assays of GBRs.
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Table S2 Primers used for cloning GBRs into
pGL4.10E4TATA reporter plasmids.
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